Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Albert Candia
Institution:
IGM Biosciences (United States)
Observed institution:
IGM Biosciences (United States)
ORCID:
0000-0003-0447-4046
Observed ORCID:
0000-0003-0447-4046
OpenAlex ID:
A5065094109
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
·
Clinical Cancer Research
·
8
Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
PDF
Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
Supplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
PDF
Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
PDF
Data from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
PDF
Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
Supplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025
·
Antoni Ribas
, Mohammed M. Milhem
, et al.
PDF
Show more works
View as search
Works count:
11
Citation count:
8
H-index:
1
I10-index:
Year
Topic
Type
